Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

Premium Phosphosite-Specific 7TM Antibodies

Phosphorylation of intracellular serine and threonine residues is the most important post translational modification of G protein-coupled receptors (GPCRs) also called heptahelical or seven transmembrane receptors (7TMR). After agonist exposure, these receptors acquire an active conformation, which is recognized by a family of highly specialized GPCR kinases (GRKs). Agonist-driven phosphorylation by GRKs regulates acute receptor desensitization, arrestin recruitment, internalization, post-activation signaling, long-term tolerance and drug addiction. Phosphosite-specific 7TM antibodies are designed to specifically detect agonist-activated GPCRs. In fact, recent work shows that ligand profiling using phosphosite-specific 7TM antibodies provides valuble information on ligand bias beyond that obtained with conventional ß-arrestin recruitment assays. Phosphosite-specific 7TM antibodies are novel tools for GPCR research that can be used to:

  • profile agonist properties of novel GPCR ligands
  • decipher the phosphorylation barcode of GPCRs
  • determine the spatial and temporal dynamics of receptor phosphorylation
  • identify relevant kinases and phosphatases for GPCR phosphorylation and dephosphoryation

Lifecycle3

Schematic representation of the G protein-coupled receptor phosphorylation / dephosphorylation cycle. GRK, G protein-coupled receptor kinase; PKC, protein kinase C; cPP1, catalytic subunit of protein phosphatase 1; R*, activated GPCR; CCP, clathrin-coated pit. 

Close filters
14 From 43
No results were found for the filter!
NEW
Agonist-induced Threonine370/Threonine371 phosphorylation of the CXC Chemokine Receptor 5
pT370/pT371-CXCR5 (phospho-CXC Chemokine...
Threonine370/Threonine371 (T370/T371) is a major phosphorylation site of the CXCR5 receptor. The pT370/pT371-CXCR5 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T370/T371...
£ 335.00 *
Details
NEW
Agonist-induced Threonine347 phosphorylation of the CXC Chemokine Receptor 2
pT347-CXCR2 (phospho-CXC Chemokine Receptor 2...
Threonine347 (T347) is a major phosphorylation site of the CXCR2 receptor. The pT347-CXCR2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T347 phosphorylation is a key...
£ 335.00 *
Details
NEW
Agonist-induced Serine351/Serine352 phosphorylation of the CXC Chemokine Receptor 2
pS351/pS352-CXCR2 (phospho-CXC Chemokine...
Serine351/Serine352 (S351/S352) is a major phosphorylation site of the CXCR2 receptor. The pS351/pS352-CXCR2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S351/S352...
£ 335.00 *
Details
NEW
Agonist-induced Serine353/Threonine356 phosphorylation of the CXC Chemokine Receptor 2
pS353/pT356-CXCR2 (phospho-CXC Chemokine...
Serine353/Threonine356 (S353/T356) is a major phosphorylation site of the CXCR2 receptor. The pS353/pT356-CXCR2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. S353/T356...
£ 335.00 *
Details
NEW
Agonist-induced Threonine353 phosphorylation of the Chemokine Receptor 10
pT353-CCR10 (phospho-Chemokine Receptor 10...
Threonine353 (T353) is a major phosphorylation site of the CCR10 receptor. The pT353-CCR10 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T353 phosphorylation is a key regulator...
£ 335.00 *
Details
NEW
Agonist-induced Threonine355 phosphorylation of the Chemokine Receptor 10
pT355-CCR10 (phospho-Chemokine Receptor 10...
Threonine355 (T355) is a major phosphorylation site of the CCR10 receptor. The pT355-CCR10 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T355 phosphorylation is a key regulator...
£ 335.00 *
Details
NEW
Immunohistochemical identification of Complement C5a Receptor 1 in Spleen
C5a1 (GP-IHC-grade), Complement C5a Receptor 1...
The C5a1 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human Complement 5a Receptor 1. It can be used to detect total C5a1 receptors in Western blots independent of phosphorylation. The C5a1...
£ 335.00 *
Details
NEW
Agonist-induced Serine594/Threonine597/Serine599 phosphorylation of the SMO Receptor
pS594/pT597/pS599-SMO (phospho-SMO Receptor...
Serine594/Threonine597/Serine599 (S594/S597/S599) is major GRK2 phosphorylation site of the SMO receptor. The pS594/pT597/pS599-SMO antibody detects phosphorylation in response to agonists. The pS594/pT597/pS599-SMO antibody can be used...
£ 335.00 *
Details
NEW
Agonist-induced Serine351/Serine354 phosphorylation of the Neuropeptide Y
pS351/pS354-NPY2 (phospho-Neuropeptide Y...
Serine351/Serine354 (S351/S354) is a major phosphorylation site of the Neuropeptide Y Receptor 2. The pS351/pS354-NPY2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation....
£ 335.00 *
Details
NEW
Agonist-induced Serine354/Threonine356 phosphorylation of the Neuropeptide Y receptor 2
pS354/pT356-NPY2 (phospho-Neuropeptide Y...
Serine354Threonine356 (S354/T356) is a major phosphorylation site of the Neuropeptide Y Receptor 2. The pS354/pT356-NPY2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation....
£ 335.00 *
Details
NEW
Agonist-induced Serine369/Serine374 phosphorylation of the Neuropeptide Y receptor 2
pS369/pS374-NPY2 (phospho-Neuropeptide Y...
Serine369/Serine374 (S369/S374) is a major phosphorylation site of the Neuropeptide Y Receptor 2. The pS369/pS374-NPY2 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation....
£ 335.00 *
Details
NEW
Agonist-induced Threonine362/Serine363 phosphorylation of the Neuropeptide Y receptor 1
pT362/pS363-NPY1 (phospho-Neuropeptide Y...
Threonine362/Serine363 (T362/S363) is a major phosphorylation site of the Neuropeptide Y Receptor 1. The pT362/pS363-NPY1 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation....
£ 335.00 *
Details
NEW
gonist-induced Threonine357/Serine360 phosphorylation of the Neuropeptide Y receptor 1
pT357/pS360-NPY1 (phospho-Neuropeptide Y...
Threonine357/Serine360 (T357/S360) is a major phosphorylation site of the Neuropeptide Y Receptor 1. The pT357/pS360-NPY1 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation....
£ 335.00 *
Details
NEW
Agonist-induced Threonine340 phosphorylation of the Chemokine Receptor 5
pT340-CCR5 (phospho-Chemokine Receptor 5 Antibody)
Threonine340 (T340) is a major phosphorylation site of the CCR5 receptor. The pT340-CCR5 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T340 phosphorylation is a key regulator of...
£ 335.00 *
Details
NEW
Agonist-induced Serine429 phosphorylation of the Cannabinoid Receptor 1
pS429-CB1 (phospho-Cannabinoid Receptor 1...
Serine429 (S429) is major phosphorylation site of the Cannabinoid Receptor 1 (CB1). The pS429-CB1 antibody detects phosphorylation in response to agonists. S429 phosphorylation is likely to be involved in efficient ligand sequestration...
£ 335.00 *
Details
NEW
Agonist-induced Serine441 phosphorylation of the Cannabinoid Receptor 1
pS441-CB1 (phospho-Cannabinoid Receptor 1...
Serine441 (S441) is major phosphorylation site of the Cannabinoid Receptor 1 (CB1). The pS441-CB1 antibody detects phosphorylation in response to agonists. S441 phosphorylation is likely to be involved in efficient ligand sequestration...
£ 335.00 *
Details
14 From 43

For further reading refer to:

Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636. doi:10.1016/j.tips.2017.04.002. Epub 2017 May 4. Review. PubMed PMID: 28478994.

Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018 Jul 17;11(539). pii: eaas9609. doi: 10.1126/scisignal.aas9609. PubMed PMID: 30018083.

Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019 Jan 21;10(1):367. doi: 10.1038/s41467-018-08162-1. PubMed PMID: 30664663; PubMed Central PMCID: PMC6341117.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072. PubMed PMID: 30914485; PubMed Central PMCID: PMC6934085.

Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin. Cell Rep. 2019 Feb 5;26(6):1473-1488.e9. doi: 10.1016/j.celrep.2019.01.049. PubMed PMID: 30726732.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3. PubMed PMID: 24629717; PubMed Central PMCID: PMC4119866.

For further reading refer to: Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636.... read more »
Close window
Premium Phosphosite-Specific 7TM Antibodies

For further reading refer to:

Kliewer A, Reinscheid RK, Schulz S. Emerging Paradigms of G Protein-Coupled Receptor Dephosphorylation. Trends Pharmacol Sci. 2017 Jul;38(7):621-636. doi:10.1016/j.tips.2017.04.002. Epub 2017 May 4. Review. PubMed PMID: 28478994.

Miess E, Gondin AB, Yousuf A, Steinborn R, Mösslein N, Yang Y, Göldner M, Ruland JG, Bünemann M, Krasel C, Christie MJ, Halls ML, Schulz S, Canals M. Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization. Sci Signal. 2018 Jul 17;11(539). pii: eaas9609. doi: 10.1126/scisignal.aas9609. PubMed PMID: 30018083.

Kliewer A, Schmiedel F, Sianati S, Bailey A, Bateman JT, Levitt ES, Williams JT, Christie MJ, Schulz S. Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects. Nat Commun. 2019 Jan 21;10(1):367. doi: 10.1038/s41467-018-08162-1. PubMed PMID: 30664663; PubMed Central PMCID: PMC6341117.

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci Signal. 2019 Mar 26;12(574). pii: eaau8072. doi: 10.1126/scisignal.aau8072. PubMed PMID: 30914485; PubMed Central PMCID: PMC6934085.

Saaber F, Schütz D, Miess E, Abe P, Desikan S, Ashok Kumar P, Balk S, Huang K, Beaulieu JM, Schulz S, Stumm R. ACKR3 Regulation of Neuronal Migration Requires ACKR3 Phosphorylation, but Not β-Arrestin. Cell Rep. 2019 Feb 5;26(6):1473-1488.e9. doi: 10.1016/j.celrep.2019.01.049. PubMed PMID: 30726732.

Glück L, Loktev A, Moulédous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014 Nov 15;76(10):767-74. doi: 10.1016/j.biopsych.2014.01.021. Epub 2014 Feb 3. PubMed PMID: 24629717; PubMed Central PMCID: PMC4119866.

Recently viewed